CCR4 Antagonists Inhibit T reg Trafficking into the Tumor Microenvironment.

Autor:	Ketcham JM; FLX Bio, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States., Marshall LA; FLX Bio, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States., Talay O; FLX Bio, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States.
Jazyk:	angličtina
Zdroj:	ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Sep 10; Vol. 9 (10), pp. 953-955. Date of Electronic Publication: 2018 Sep 10 (Print Publication: 2018).
DOI:	10.1021/acsmedchemlett.8b00351
Abstrakt:	Recruitment of naturally occurring suppressive CD4 + , CD25 + , and FOXP3 + regulatory T cells (T reg ) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human T reg express CCR4 and can be recruited to the TME through the C-C chemokines CCL17 and CCL22. We have recently developed a series of potent, orally bioavailable small molecule antagonists of CCR4 that can block recruitment of T reg into the TME. Competing Interests: The authors declare the following competing financial interest(s): The authors of this manuscript are employees of FLX Bio, Inc.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu